or Try an Advanced Search...

    Technical Analysis for CRVO - CervoMed Inc.

    Grade Last Price % Change Price Change
    D 16.12 -5.84% -1.00
    CRVO closed down 5.84 percent on Monday, July 1, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical CRVO trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Volume Surge Other -5.84%
    Calm After Storm Range Contraction -5.84%
    Doji - Bullish? Reversal -5.84%
    Older End-of-Day Signals for CRVO ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band about 8 hours ago
    Down 5% about 8 hours ago
    Down 3% about 8 hours ago
    Fell Below Previous Day's Low about 8 hours ago
    Down 2 % about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CRVO Chart by TradingView
    Basic chart:

    Profile

    CervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Development Cancer Treatment Oncology Chemotherapy Radiation Ophthalmology Dermatology Oxygen Blastoma Macular Degeneration Glioblastoma Radiation Therapy Signal Transduction Cancer Cell Acne Brain Tumor mTOR Glioblastoma Multiforme Oncology Applications Acne Vulgaris

    Is CRVO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 31 CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…
    May 15 CervoMed GAAP EPS of -$0.41 beats by $0.01, revenue of $2.35M beats by $0.35M
    May 15 CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    Apr 2 Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
    Apr 2 CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
    Apr 1 CervoMed GAAP EPS of -$0.82 beats by $1.23, revenue of $7.14M beats by $3.09M
    Apr 1 CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    Mar 5 CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
    Feb 21 CervoMed to Participate in the BIO CEO and Investor Conference
    Feb 20 CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
    See more CRVO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 26.3789
    52 Week Low 4.14
    Average Volume 56,057
    200-Day Moving Average 14.05
    50-Day Moving Average 21.32
    20-Day Moving Average 19.12
    10-Day Moving Average 18.82
    Average True Range 2.08
    RSI (14) 31.97
    ADX 14.22
    +DI 12.81
    -DI 22.41
    Chandelier Exit (Long, 3 ATRs) 16.33
    Chandelier Exit (Short, 3 ATRs) 21.64
    Upper Bollinger Bands 21.44
    Lower Bollinger Band 16.81
    Percent B (%b) -0.15
    BandWidth 24.22
    MACD Line -0.92
    MACD Signal Line -0.69
    MACD Histogram -0.2316
    Fundamentals Value
    Market Cap 91.47 Million
    Num Shares 5.67 Million
    EPS -5.59
    Price-to-Earnings (P/E) Ratio -2.88
    Price-to-Sales 11.27
    Price-to-Book 5.48
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.87
    Resistance 3 (R3) 18.93 18.08 18.41
    Resistance 2 (R2) 18.08 17.38 18.05 18.25
    Resistance 1 (R1) 17.10 16.95 16.68 17.04 18.10
    Pivot Point 16.25 16.25 16.04 16.22 16.25
    Support 1 (S1) 15.27 15.55 14.85 15.21 14.14
    Support 2 (S2) 14.42 15.12 14.39 13.99
    Support 3 (S3) 13.44 14.42 13.83
    Support 4 (S4) 13.38